{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mungle T"],"funding":["Indian Council of Medical Research","Wellcome Trust"],"pagination":["3499-3508"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9939102"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(3)"],"pubmed_abstract":["<h4>Background</h4>To evaluate the treatment cost and cost effectiveness of a risk-stratified therapy to treat pediatric acute lymphoblastic leukemia (ALL) in India.<h4>Methods</h4>The cost of total treatment duration was calculated for a retrospective cohort of ALL children treated at a tertiary care facility. Children were risk stratified into standard (SR), intermediate (IR) and high (HR) for B-cell precursor ALL, and T-ALL. Cost of therapy was obtained from the hospital electronic billing systems and details of outpatient (OP) and inpatient (IP) from electronic medical records. Cost effectiveness was calculated in disability-adjusted life years.<h4>Results</h4>One hundred and forty five patients, SR (50), IR (36), HR (39), and T-ALL (20) were analyzed. Median cost of the entire treatme"],"journal":["Cancer medicine"],"pubmed_title":["Comparative treatment costs of risk-stratified therapy for childhood acute lymphoblastic leukemia in India."],"pmcid":["PMC9939102"],"funding_grant_id":["79/159/2015/NCD‐II"],"pubmed_authors":["Ghara N","Ghosh D","Saha V","Mungle T","Das N","Das P","Pal S","Arora RS","Gogoi MP","Bhakta N","Krishnan S"],"additional_accession":[]},"is_claimable":false,"name":"Comparative treatment costs of risk-stratified therapy for childhood acute lymphoblastic leukemia in India.","description":"<h4>Background</h4>To evaluate the treatment cost and cost effectiveness of a risk-stratified therapy to treat pediatric acute lymphoblastic leukemia (ALL) in India.<h4>Methods</h4>The cost of total treatment duration was calculated for a retrospective cohort of ALL children treated at a tertiary care facility. Children were risk stratified into standard (SR), intermediate (IR) and high (HR) for B-cell precursor ALL, and T-ALL. Cost of therapy was obtained from the hospital electronic billing systems and details of outpatient (OP) and inpatient (IP) from electronic medical records. Cost effectiveness was calculated in disability-adjusted life years.<h4>Results</h4>One hundred and forty five patients, SR (50), IR (36), HR (39), and T-ALL (20) were analyzed. Median cost of the entire treatme","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-08-18T09:53:19.536Z","creation":"2025-04-05T23:49:59.374Z"},"accession":"S-EPMC9939102","cross_references":{"pubmed":["36812120"],"doi":["10.1002/cam4.5140"]}}